The U.S. Food and Drug Administration accepted the New Drug Application for zipalertinib on April 28 2026, a key regulatory milestone that could unlock up to $130 million in milestone payments and a 50 % share of U.S. sales revenue for Cullinan Therapeutics. The acceptance follows a partnership with Taiho Oncology, which will co‑develop and commercialize the drug in the United States.
Zipalertinib’s clinical data, derived from the Phase 2b portion of the REZILIENT1 trial, show an objective response rate of 35.2% overall, rising to 40 % in patients who had received platinum‑based chemotherapy but not prior exon 20 insertion‑targeted therapies. The drug also demonstrated activity in patients previously treated with amivantamab (30 % response) and in those with baseline brain metastases (31 % response), indicating potential central nervous system penetration and a broader therapeutic window.
The drug will compete in a market that currently includes the antibody–drug conjugate amivantamab (Rybrevant) and the oral agent sunvozertinib (Zegfrovy). Zipalertinib offers an oral, next‑generation irreversible EGFR inhibitor that selectively targets exon 20 insertion mutations while sparing wild‑type EGFR, potentially reducing off‑target toxicity and providing a more convenient dosing schedule for patients.
Financially, the acceptance positions Cullinan to receive milestone payments and a revenue share that could significantly boost its cash flow. The company reported $439 million in cash and investments as of December 31 2025, giving it a runway into 2029 and the flexibility to invest in its pipeline, which includes CLN‑978 for autoimmune disease and CLN‑049 for acute myeloid leukemia.
The partnership with Taiho Oncology extends beyond zipalertinib; Taiho will handle U.S. commercialization, while Cullinan retains a 50 % share of U.S. sales revenue. This collaboration leverages Taiho’s established sales infrastructure and Cullinan’s clinical expertise, accelerating the drug’s path to market and enhancing the company’s strategic positioning in oncology.
"FDA acceptance of the zipalertinib NDA is an important step toward making zipalertinib available for people living with NSCLC with EGFR exon 20 insertion mutations, who continue to face limited treatment options," said Jeffrey Jones, MD, MBA, Chief Medical Officer of Cullinan Therapeutics. "The FDA's acceptance of the NDA represents an important milestone, reflecting the scientific and clinical data accumulated to date. We will continue to work closely with Taiho Oncology, Cullinan Therapeutics and the FDA throughout the review process, with the shared goal of ultimately delivering a new treatment option to patients with NSCLC and EGFR exon 20 insertion mutations."
revised_sentiment_rating":3}]}
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.